<DOC>
	<DOCNO>NCT02001181</DOCNO>
	<brief_summary>The study conduct evaluate efficacy , safety tolerability 2 % tofacitinib ointment ( 20 mg/g ) BID ( twice daily ) subject mild moderate atopic dermatitis compare placebo ( vehicle ) BID 4 week .</brief_summary>
	<brief_title>Tofacitinib Ointment For Atopic Dermatitis ( Atopic Eczema )</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Have clinical diagnosis atopic dermatitis ( also know atopic eczema ) least 6 month prior Day 1 clinically stable least 1 month prior Day 1 confirm atopic dermatitis accord criterion Hanifin Rajka . Have PGA score 2 ( mild ) 3 ( moderate ) Day 1 . Have atopic dermatitis head ( include face , exclude hair bear scalp ) , neck , trunk ( exclude groin genitals ) , limbs include palm sol cover least 2 % total body surface area ( BSA ) include 20 % total BSA Day 1 . At least 2 % total BSA need head ( include face , exclude hair bear scalp ) , neck , trunk ( exclude groin genitals ) , limb ( exclude palm sol ) . Evidence certain skin conditions/infections baseline Currently atopic dermatitis groin , genitals , palm sol Have certain laboratory abnormality baseline Females pregnant , breastfeeding , childbearing potential use highly effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Atopic Eczema</keyword>
	<keyword>Eczema</keyword>
	<keyword>topical treatment</keyword>
	<keyword>skin disease</keyword>
	<keyword>tofacitinib</keyword>
	<keyword>CP-690</keyword>
	<keyword>550</keyword>
	<keyword>Janus Kinase inhibitor</keyword>
</DOC>